A carregar...
Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
Monoclonal antibody (mAb) therapy has rapidly changed the field of cancer therapy. In 1997, the CD20-targeting mAb rituximab was the first mAb to be approved by the U.S. Food and Drug Administration (FDA) for treatment of cancer. Within two decades, dozens of mAbs entered the clinic for treatment of...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI AG
2020-10-01
|
| Colecção: | Cancers |
| Assuntos: | |
| Acesso em linha: | https://www.mdpi.com/2072-6694/12/10/3041 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|